Prostate Cancer Coverage from Every Angle

TAT 2020: IL-18 and Anticancer Immunity in Prostate Cancer

By: Joshua Swore
Posted: Wednesday, March 25, 2020

An e-poster from the proceedings of the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2020 (Abstract 12P) revealed that interleukin-18 (IL-18) may improve the anticancer immunity of gamma delta (Vγ2Vδ2) T cells in prostate cancer. The study’s basis relies on using IL-18 conjointly with other cytokines to optimize T cells for anticancer immunity function.

According to Mohanad H. Nada, MD PhD, of the University of Iowa, Iowa City, and colleagues,“Our findings conclude that using IL-18 in combination with IL-2 or IL-15 results in increasing the yield, balancing out the memory subsets, and promoting the anticancer immunity of human Vγ2Vδ2 T cells.”

The authors used peripheral blood mononuclear cells for ex vivo expansion of Vγ2Vδ2 T cells. The cells were pulsed with zoledronate in the presence of the cytokines IL-2, IL-5, and/or, IL-18. Next, the researchers used multicolor flowcCytometry to observe cell functionality via cytokine expression. T cells and human prostate cancer cells (PC-3) were then cultured together to assess the cytotoxicity of activated Vγ2Vδ2 T cells, which was measured by CD107a expression.

The study demonstrated that treating Vγ2Vδ2 T cells with cytokines increased the overall number of activated T cells. The memory of T cells was variably based on the combinations of cytokines. IL-18 displayed increased memory at early and central subsets when in combination with IL-2 but increased late memory with IL-15. Lastly, the researchers observed increased CD107a expression on activated Vγ2Vδ2 T cells when cultured with PC-3 cells, indicating increased antitumor activity.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.